APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody for Gastric Cancer

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Monoclonal Antibody for Gastric Cancer Market Outlook and Growth Opportunities 2026

Report ID 174014160426 December 2025194 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody for Gastric Cancer Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody for Gastric Cancer Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody for Gastric Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody for Gastric Cancer Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody for Gastric Cancer Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody for Gastric Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Monoclonal Antibody for Gastric Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibody for Gastric Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibody for Gastric Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Monoclonal Antibody for Gastric Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Monoclonal Antibody for Gastric Cancer market include Innovent Biologics, Inc, Henlius, Merck & Co., Inc, Eli Lilly & Co, CStone Pharmaceuticals, Astellas Pharma, Inc., Genentech, Bristol Myers Squibb Co and BeiGene Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Monoclonal Antibody for Gastric Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monoclonal Antibody for Gastric Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monoclonal Antibody for Gastric Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Monoclonal Antibody for Gastric Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

Monoclonal Antibody for Gastric Cancer Segment by Company

Innovent Biologics, Inc

Henlius

Merck & Co., Inc

Eli Lilly & Co

CStone Pharmaceuticals

Astellas Pharma, Inc.

Genentech

Bristol Myers Squibb Co

BeiGene Ltd

Monoclonal Antibody for Gastric Cancer Segment by Type

5 mg/mL

4 mg/mL

10 mg/mL

Monoclonal Antibody for Gastric Cancer Segment by Application

Hospital

Clinic

Others

Monoclonal Antibody for Gastric Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Monoclonal Antibody for Gastric Cancer status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Monoclonal Antibody for Gastric Cancer market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Monoclonal Antibody for Gastric Cancer significant trends, drivers, influence factors in global and regions.

6. To analyze Monoclonal Antibody for Gastric Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody for Gastric Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody for Gastric Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody for Gastric Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Monoclonal Antibody for Gastric Cancer market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Monoclonal Antibody for Gastric Cancer industry.

Chapter 3: Detailed analysis of Monoclonal Antibody for Gastric Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Monoclonal Antibody for Gastric Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Monoclonal Antibody for Gastric Cancer in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Monoclonal Antibody for Gastric Cancer Industry Trends Table 2. Monoclonal Antibody for Gastric Cancer Industry Drivers Table 3. Monoclonal Antibody for Gastric Cancer Industry Opportunities and Challenges Table 4. Monoclonal Antibody for Gastric Cancer Industry Restraints Table 5. Global Monoclonal Antibody for Gastric Cancer Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Monoclonal Antibody for Gastric Cancer Revenue Share by Company (2021-2026) Table 7. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Company (2021-2026) Table 9. Global Monoclonal Antibody for Gastric Cancer Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Monoclonal Antibody for Gastric Cancer Company Ranking, (2024-2026) & (USD Million) Table 11. Global Monoclonal Antibody for Gastric Cancer Key Company Manufacturing Base & Headquarters Table 12. Global Monoclonal Antibody for Gastric Cancer Company, Product Type & Application Table 13. Global Monoclonal Antibody for Gastric Cancer Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Monoclonal Antibody for Gastric Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5 mg/mL Table 18. Significant Companies of 4 mg/mL Table 19. Significant Companies of 10 mg/mL Table 20. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Type (2021-2026) Table 24. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Type (2027-2032) Table 25. Global Monoclonal Antibody for Gastric Cancer Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Monoclonal Antibody for Gastric Cancer Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Monoclonal Antibody for Gastric Cancer Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Type (2021-2026) Table 29. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Others Table 33. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Application (2021-2026) Table 37. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Application (2027-2032) Table 38. Global Monoclonal Antibody for Gastric Cancer Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Monoclonal Antibody for Gastric Cancer Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Monoclonal Antibody for Gastric Cancer Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Application (2021-2026) Table 42. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Application (2027-2032) Table 43. Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Monoclonal Antibody for Gastric Cancer Sales by Region (2021-2026) & (K Units) Table 45. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2021-2026) Table 46. Global Monoclonal Antibody for Gastric Cancer Sales by Region (2027-2032) & (K Units) Table 47. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2027-2032) Table 48. Global Monoclonal Antibody for Gastric Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Monoclonal Antibody for Gastric Cancer Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Region (2021-2026) Table 51. Global Monoclonal Antibody for Gastric Cancer Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Region (2027-2032) Table 53. Global Monoclonal Antibody for Gastric Cancer Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Monoclonal Antibody for Gastric Cancer Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Monoclonal Antibody for Gastric Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Monoclonal Antibody for Gastric Cancer Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2026) & (K Units) Table 58. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021-2026) Table 59. Global Monoclonal Antibody for Gastric Cancer Sales by Country (2027-2032) & (K Units) Table 60. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2027-2032) Table 61. Global Monoclonal Antibody for Gastric Cancer Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Monoclonal Antibody for Gastric Cancer Sales Value Market Share by Country (2021-2026) Table 63. Global Monoclonal Antibody for Gastric Cancer Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Monoclonal Antibody for Gastric Cancer Sales Value Market Share by Country (2027-2032) Table 65. Innovent Biologics, Inc Company Information Table 66. Innovent Biologics, Inc Business Overview Table 67. Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Product Portfolio Table 69. Innovent Biologics, Inc Recent Development Table 70. Henlius Company Information Table 71. Henlius Business Overview Table 72. Henlius Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Henlius Monoclonal Antibody for Gastric Cancer Product Portfolio Table 74. Henlius Recent Development Table 75. Merck & Co., Inc Company Information Table 76. Merck & Co., Inc Business Overview Table 77. Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Product Portfolio Table 79. Merck & Co., Inc Recent Development Table 80. Eli Lilly & Co Company Information Table 81. Eli Lilly & Co Business Overview Table 82. Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Product Portfolio Table 84. Eli Lilly & Co Recent Development Table 85. CStone Pharmaceuticals Company Information Table 86. CStone Pharmaceuticals Business Overview Table 87. CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Product Portfolio Table 89. CStone Pharmaceuticals Recent Development Table 90. Astellas Pharma, Inc. Company Information Table 91. Astellas Pharma, Inc. Business Overview Table 92. Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Product Portfolio Table 94. Astellas Pharma, Inc. Recent Development Table 95. Genentech Company Information Table 96. Genentech Business Overview Table 97. Genentech Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Genentech Monoclonal Antibody for Gastric Cancer Product Portfolio Table 99. Genentech Recent Development Table 100. Bristol Myers Squibb Co Company Information Table 101. Bristol Myers Squibb Co Business Overview Table 102. Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Product Portfolio Table 104. Bristol Myers Squibb Co Recent Development Table 105. BeiGene Ltd Company Information Table 106. BeiGene Ltd Business Overview Table 107. BeiGene Ltd Monoclonal Antibody for Gastric Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. BeiGene Ltd Monoclonal Antibody for Gastric Cancer Product Portfolio Table 109. BeiGene Ltd Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Monoclonal Antibody for Gastric Cancer Distributors List Table 113. Monoclonal Antibody for Gastric Cancer Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Monoclonal Antibody for Gastric Cancer Product Image Figure 2. Global Monoclonal Antibody for Gastric Cancer Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032) & (US$ Million) Figure 4. Global Monoclonal Antibody for Gastric Cancer Sales (2021-2032) & (K Units) Figure 5. Global Monoclonal Antibody for Gastric Cancer Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Monoclonal Antibody for Gastric Cancer Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5 mg/mL Image Figure 10. 4 mg/mL Image Figure 11. 10 mg/mL Image Figure 12. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Type (2021-2032) Figure 15. Global Monoclonal Antibody for Gastric Cancer Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Monoclonal Antibody for Gastric Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Monoclonal Antibody for Gastric Cancer Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Application (2021-2032) Figure 24. Global Monoclonal Antibody for Gastric Cancer Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Monoclonal Antibody for Gastric Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Application (2021-2032) Figure 27. Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Monoclonal Antibody for Gastric Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032) & (US$ Million) Figure 32. North America Monoclonal Antibody for Gastric Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Monoclonal Antibody for Gastric Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Monoclonal Antibody for Gastric Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032) & (US$ Million) Figure 38. South America Monoclonal Antibody for Gastric Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Monoclonal Antibody for Gastric Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Monoclonal Antibody for Gastric Cancer Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Monoclonal Antibody for Gastric Cancer Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 5 mg/mL
  • 4 mg/mL
  • 10 mg/mL
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Innovent Biologics, Inc
  • Henlius
  • Merck & Co., Inc
  • Eli Lilly & Co
  • CStone Pharmaceuticals
  • Astellas Pharma, Inc.
  • Genentech
  • Bristol Myers Squibb Co
  • BeiGene Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032)
  4. 1.2.2 Global Monoclonal Antibody for Gastric Cancer Sales Volume (2021-2032)
  5. 1.2.3 Global Monoclonal Antibody for Gastric Cancer Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Monoclonal Antibody for Gastric Cancer Market Dynamics
  1. 2.1 Monoclonal Antibody for Gastric Cancer Industry Trends
  2. 2.2 Monoclonal Antibody for Gastric Cancer Industry Drivers
  3. 2.3 Monoclonal Antibody for Gastric Cancer Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody for Gastric Cancer Industry Restraints
3 Monoclonal Antibody for Gastric Cancer Market by Company
  1. 3.1 Global Monoclonal Antibody for Gastric Cancer Company Revenue Ranking in 2025
  2. 3.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Company (2021-2026)
  3. 3.3 Global Monoclonal Antibody for Gastric Cancer Sales Volume by Company (2021-2026)
  4. 3.4 Global Monoclonal Antibody for Gastric Cancer Average Price by Company (2021-2026)
  5. 3.5 Global Monoclonal Antibody for Gastric Cancer Company Ranking (2024-2026)
  6. 3.6 Global Monoclonal Antibody for Gastric Cancer Company Manufacturing Base and Headquarters
  7. 3.7 Global Monoclonal Antibody for Gastric Cancer Company Product Type and Application
  8. 3.8 Global Monoclonal Antibody for Gastric Cancer Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Monoclonal Antibody for Gastric Cancer Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Monoclonal Antibody for Gastric Cancer Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Monoclonal Antibody for Gastric Cancer Market by Type
  1. 4.1 Monoclonal Antibody for Gastric Cancer Type Introduction
  2. 4.1.1 5 mg/mL
  3. 4.1.2 4 mg/mL
  4. 4.1.3 10 mg/mL
  5. 4.2 Global Monoclonal Antibody for Gastric Cancer Sales Volume by Type
  6. 4.2.1 Global Monoclonal Antibody for Gastric Cancer Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Monoclonal Antibody for Gastric Cancer Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Monoclonal Antibody for Gastric Cancer Sales Value by Type
  10. 4.3.1 Global Monoclonal Antibody for Gastric Cancer Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Monoclonal Antibody for Gastric Cancer Sales Value by Type (2021-2032)
  12. 4.3.3 Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Type (2021-2032)
5 Monoclonal Antibody for Gastric Cancer Market by Application
  1. 5.1 Monoclonal Antibody for Gastric Cancer Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Monoclonal Antibody for Gastric Cancer Sales Volume by Application
  6. 5.2.1 Global Monoclonal Antibody for Gastric Cancer Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Monoclonal Antibody for Gastric Cancer Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Monoclonal Antibody for Gastric Cancer Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Monoclonal Antibody for Gastric Cancer Sales Value by Application
  10. 5.3.1 Global Monoclonal Antibody for Gastric Cancer Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Monoclonal Antibody for Gastric Cancer Sales Value by Application (2021-2032)
  12. 5.3.3 Global Monoclonal Antibody for Gastric Cancer Sales Value Share by Application (2021-2032)
6 Monoclonal Antibody for Gastric Cancer Regional Sales and Value Analysis
  1. 6.1 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Monoclonal Antibody for Gastric Cancer Sales by Region (2021-2032)
  3. 6.2.1 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2021-2026
  4. 6.2.2 Global Monoclonal Antibody for Gastric Cancer Sales by Region (2027-2032)
  5. 6.3 Global Monoclonal Antibody for Gastric Cancer Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Monoclonal Antibody for Gastric Cancer Sales Value by Region (2021-2032)
  7. 6.4.1 Global Monoclonal Antibody for Gastric Cancer Sales Value by Region: 2021-2026
  8. 6.4.2 Global Monoclonal Antibody for Gastric Cancer Sales Value by Region (2027-2032)
  9. 6.5 Global Monoclonal Antibody for Gastric Cancer Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032)
  12. 6.6.2 North America Monoclonal Antibody for Gastric Cancer Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032)
  15. 6.7.2 Europe Monoclonal Antibody for Gastric Cancer Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Monoclonal Antibody for Gastric Cancer Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032)
  21. 6.9.2 South America Monoclonal Antibody for Gastric Cancer Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Monoclonal Antibody for Gastric Cancer Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Monoclonal Antibody for Gastric Cancer Sales Value Share by Country, 2025 VS 2032
7 Monoclonal Antibody for Gastric Cancer Country-level Sales and Value Analysis
  1. 7.1 Global Monoclonal Antibody for Gastric Cancer Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Monoclonal Antibody for Gastric Cancer Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2032)
  4. 7.3.1 Global Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2026)
  5. 7.3.2 Global Monoclonal Antibody for Gastric Cancer Sales by Country (2027-2032)
  6. 7.4 Global Monoclonal Antibody for Gastric Cancer Sales Value by Country (2021-2032)
  7. 7.4.1 Global Monoclonal Antibody for Gastric Cancer Sales Value by Country (2021-2026)
  8. 7.4.2 Global Monoclonal Antibody for Gastric Cancer Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Monoclonal Antibody for Gastric Cancer Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Monoclonal Antibody for Gastric Cancer Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Monoclonal Antibody for Gastric Cancer Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Innovent Biologics, Inc
  2. 8.1.1 Innovent Biologics, Inc Company Information
  3. 8.1.2 Innovent Biologics, Inc Business Overview
  4. 8.1.3 Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Product Portfolio
  6. 8.1.5 Innovent Biologics, Inc Recent Developments
  7. 8.2 Henlius
  8. 8.2.1 Henlius Company Information
  9. 8.2.2 Henlius Business Overview
  10. 8.2.3 Henlius Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Henlius Monoclonal Antibody for Gastric Cancer Product Portfolio
  12. 8.2.5 Henlius Recent Developments
  13. 8.3 Merck & Co., Inc
  14. 8.3.1 Merck & Co., Inc Company Information
  15. 8.3.2 Merck & Co., Inc Business Overview
  16. 8.3.3 Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Product Portfolio
  18. 8.3.5 Merck & Co., Inc Recent Developments
  19. 8.4 Eli Lilly & Co
  20. 8.4.1 Eli Lilly & Co Company Information
  21. 8.4.2 Eli Lilly & Co Business Overview
  22. 8.4.3 Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Product Portfolio
  24. 8.4.5 Eli Lilly & Co Recent Developments
  25. 8.5 CStone Pharmaceuticals
  26. 8.5.1 CStone Pharmaceuticals Company Information
  27. 8.5.2 CStone Pharmaceuticals Business Overview
  28. 8.5.3 CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Product Portfolio
  30. 8.5.5 CStone Pharmaceuticals Recent Developments
  31. 8.6 Astellas Pharma, Inc.
  32. 8.6.1 Astellas Pharma, Inc. Company Information
  33. 8.6.2 Astellas Pharma, Inc. Business Overview
  34. 8.6.3 Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Product Portfolio
  36. 8.6.5 Astellas Pharma, Inc. Recent Developments
  37. 8.7 Genentech
  38. 8.7.1 Genentech Company Information
  39. 8.7.2 Genentech Business Overview
  40. 8.7.3 Genentech Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Genentech Monoclonal Antibody for Gastric Cancer Product Portfolio
  42. 8.7.5 Genentech Recent Developments
  43. 8.8 Bristol Myers Squibb Co
  44. 8.8.1 Bristol Myers Squibb Co Company Information
  45. 8.8.2 Bristol Myers Squibb Co Business Overview
  46. 8.8.3 Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Product Portfolio
  48. 8.8.5 Bristol Myers Squibb Co Recent Developments
  49. 8.9 BeiGene Ltd
  50. 8.9.1 BeiGene Ltd Company Information
  51. 8.9.2 BeiGene Ltd Business Overview
  52. 8.9.3 BeiGene Ltd Monoclonal Antibody for Gastric Cancer Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 BeiGene Ltd Monoclonal Antibody for Gastric Cancer Product Portfolio
  54. 8.9.5 BeiGene Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Monoclonal Antibody for Gastric Cancer Value Chain Analysis
  2. 9.1.1 Monoclonal Antibody for Gastric Cancer Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Monoclonal Antibody for Gastric Cancer Sales Mode & Process
  6. 9.2 Monoclonal Antibody for Gastric Cancer Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Monoclonal Antibody for Gastric Cancer Distributors
  9. 9.2.3 Monoclonal Antibody for Gastric Cancer Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst